Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)

Roger Li*, Paras H. Shah, Tyler F. Stewart, Jong Kil Nam, Trinity J. Bivalacqua, Donald L. Lamm, Edward M. Uchio, Daniel M. Geynisman, Joseph M. Jacob, Joshua J. Meeks, Rian Dickstein, Shane M. Pearce, Seok Ho Kang, Seung Il Jung, Ashish M. Kamat, James M. Burke, Kirk A. Keegan, Gary D. Steinberg

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology